217 related articles for article (PubMed ID: 29617099)
1. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
2. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Gandhi S; El-Dakdouki M; Basson MD; Walsh MF; Huang X; Vyas AK; Chaturvedi LS
J Nanosci Nanotechnol; 2015 Sep; 15(9):6413-22. PubMed ID: 26690867
[TBL] [Abstract][Full Text] [Related]
4. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
5. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
6. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
9. Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells.
Guo R; Wu K; Chen J; Mo L; Hua X; Zheng D; Chen P; Chen G; Xu W; Feng J
Cell Physiol Biochem; 2013; 32(6):1668-80. PubMed ID: 24356372
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
van Wijngaarden J; van Beek E; van Rossum G; van der Bent C; Hoekman K; van der Pluijm G; van der Pol MA; Broxterman HJ; van Hinsbergh VW; Löwik CW
Eur J Cancer; 2007 Jan; 43(2):433-42. PubMed ID: 17097285
[TBL] [Abstract][Full Text] [Related]
11. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
[TBL] [Abstract][Full Text] [Related]
13. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y; Bieerkehazhi S; Ma H
Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
[TBL] [Abstract][Full Text] [Related]
14. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract][Full Text] [Related]
15. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways.
Lin C; Wang L; Wang H; Yang L; Guo H; Wang X
J Cell Biochem; 2013 Sep; 114(9):2061-70. PubMed ID: 23553622
[TBL] [Abstract][Full Text] [Related]
17. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells.
Wang Z; Zhang H; Shi M; Yu Y; Wang H; Cao WM; Zhao Y; Zhang H
Sci Rep; 2016 Sep; 6():32737. PubMed ID: 27599572
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight.
Rai G; Mishra S; Suman S; Shukla Y
Phytomedicine; 2016 Mar; 23(3):233-42. PubMed ID: 26969377
[TBL] [Abstract][Full Text] [Related]
19. Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.
Sapio L; Sorvillo L; Illiano M; Chiosi E; Spina A; Naviglio S
Molecules; 2015 Sep; 20(9):15910-28. PubMed ID: 26340617
[TBL] [Abstract][Full Text] [Related]
20. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Wang H; Yu Y; Jiang Z; Cao WM; Wang Z; Dou J; Zhao Y; Cui Y; Zhang H
Sci Rep; 2016 May; 6():26456. PubMed ID: 27217076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]